Effectiveness of a Double-Carbapenem Regimen in a KPC-Producing Klebsiella pneumoniae Infection in an Immunocompromised Patient

Nuria Piedra-Carrasco, Lucia Miguel, Anna Fàbrega, Belén Viñado, David Campany, Alba Mir, María Laura Fox, Benito Almirante, Nieves Larrosa, Isabel Ruiz-Camps, Juan José González-López

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

© Copyright 2018, Mary Ann Liebert, Inc. 2018. The progressive increase of infections produced by extensively drug-resistant carbapenemase-producing Klebsiella pneumoniae (XDR-CPKP) represents an important threat to public health. Unfortunately, optimal therapeutic options are scarce. Retrospective studies have recommended combined therapy with more than one antibiotic and, more recently, a double-carbapenem regimen has been reported to be an effective alternative therapy. Here, we describe an episode of sepsis in an immunocompromised patient after allogeneic hematopoietic stem cell transplantation, caused by an XDR-CPKP. Several in vitro synergy tests revealed a synergistic effect combining ertapenem and meropenem, which were used as combination therapy achieving clinical and microbiological success.
Original languageEnglish
Pages (from-to)199-202
JournalMicrobial Drug Resistance
Volume24
Issue number2
DOIs
Publication statusPublished - 1 Mar 2018

Keywords

  • DCR
  • XDR
  • bloodstream infection
  • ertapenem
  • meropenem
  • sepsis

Fingerprint Dive into the research topics of 'Effectiveness of a Double-Carbapenem Regimen in a KPC-Producing Klebsiella pneumoniae Infection in an Immunocompromised Patient'. Together they form a unique fingerprint.

Cite this